Biosynex SA

Biosynex SA has a liquidity risk profile marked by a current ratio of 0.71, indicating that its current liabilities exceed its current assets, and a negative operating cash flow of -10.12 million EUR. The company's debt-to-equity ratio of 0.77 suggests moderate leverage, but its net income of -43.33 million EUR and operating income of -37.86 million EUR highlight significant profitability challenges. Profitability metrics are notably weak, with a return on equity of -53.78% and a return on assets of -22.26%. These figures fall well below the industry norms for Medical Equipment, Supplies & Distribution, where positive returns are typically expected. The company's gross profit of 57.42 million EUR is insufficient to cover operating expenses, contributing to the net loss. The company's revenue is concentrated in four core fields: tropical diseases, emergency markers, infectious diseases, and autoimmunity. No geographic breakdown is provided in the input data, but the company's operations are based in France, and its products are marketed globally to laboratories and medical units. The lack of geographic diversification could pose a concentration risk if demand in key regions declines. Biosynex is currently experiencing a contraction in profitability, with a net loss of 43.33 million EUR and an operating loss of 37.86 million EUR. The company's free cash flow is negative at -26.65 million EUR, and capital expenditures of -4.84 million EUR suggest ongoing investment in operations. However, without a clear revenue growth trajectory or margin improvement, the company's financial health remains at risk. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, and no dilution sources are identified in the input data. The absence of dilution risk is supported by the fact that basic and diluted shares are equal at 18.37 million. Recent financial filings and transcripts are not provided in the input data, so no specific events can be cited. However, the company's financial performance in the latest period suggests a need for strategic adjustments to improve profitability and liquidity.